--Phase II Trials of Rh-Apo2L will be Held in Twenty-Four Hospitals Throughout Mainland China-- HANGZHOU, China, Feb. 15 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, today announced the Company's subsidiary, Shanghai Qiaer Biotechnology, held a meeting on February 10, 2007 with affiliated research hospitals and scientists to formally begin the large-scale Phase II trials of Rh-Apo2L throughout mainland China. The meeting was held in Shanghai and included over seventy scientists, doctors, administrators and researchers specializing in cancer therapy from twenty-four hospitals throughout mainland China including Beijing, Shanghai and Zhejiang. Aida Pharmaceuticals and Shanghai Qiaer Biotechnology were approved by State Food and Drug Administration (SFDA) to begin the Phase II clinical trials of Rh-Apo2L in December of last year, making Rh-Apo2L the first and only anticancer therapy of its kind in the world to be approved for Phase II clinical trials. The Phase II trials will analyze the effect of Rh-Apo2L on tumors chosen from the following cancers: advanced inert lymphoma, malignant melanoma, soft tissue sarcoma, pancreatic cancer, kidney cancer, non-small cell lung cancer and colorectal cancer. The trials will analyze the specific efficacy of Rh-Apo2L in over 100 patients. Additionally, the Company will continue to analyze the dosage and effectiveness of the drug as well as other drugs' interactions with Rh-Apo2L. Mr. Jin Biao, Chairman and CEO of Aida Pharmaceuticals, stated, "We are pleased to formally announce the beginning of the large-scale Phase II clinical trials for Rh-Apo2L. We are grateful for the hard work of our research scientists and for their detailed preparation of the clinical plan. We look forward to its implementation and the successful cooperation of all the hospitals and professionals in the Phase II clinical trials. Aida and Qiaer's management teams remain confident we will complete the clinical trials of Rh-Apo2L on schedule as previously announced, and we anticipate bringing the drug to market in early 2008." About Rh-Apo2L: Rh-Apo2L is Category A, anti-tumor biological agent researched and developed by Shanghai Qiaer Biotechnology Co., Ltd., a newly acquired subsidiary of Aida Pharmaceuticals. Rh-Apo2L is a broad spectrum genetic cell apoptosis (cell- killing) agent, which the Company expects to be used for the treatment of a variety of cancerous tumors. Research and Development of Rh- Apo2L is sponsored and supported by several national and municipal funds. One patent of Rh-Apo2L has been granted by Chinese Patent Bureau, two additional patents are currently in process. To learn more about Rh-Apo2L, please visit http://www.equityperformancegroup.com/aida_einvestor_kit/QiaerBiotechFAQ.pdf. About Aida Pharmaceuticals: Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China. Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/. Contact Information: Company: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 http://www.aidapharma.com/ Investor Relations: Equity Performance Group Bethany Tomich (617) 723-1465 http://www.equityperformancegroup.com/ DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT: Investor Relations, Bethany Tomich of Equity Performance Group for Aida Pharmaceuticals, Inc., +1-617-723-1465, or Web site: http://www.aidapharma.com/

Copyright